

**Amendments to the Claims:**

1-38. (canceled)

39. (previously presented) An isolated nucleic acid having at least 80% nucleic acid sequence identity to:

- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);
- (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
- (d) the nucleic acid sequence of (SEQ ID NO: 289);
- (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
- (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

wherein the polypeptide encoded by said nucleic acid is an immunostimulant.

40. (previously presented) The isolated nucleic acid of Claim 39 having at least 85% nucleic acid sequence identity to:

- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);
- (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
- (d) the nucleic acid sequence of (SEQ ID NO: 289);
- (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
- (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

wherein the polypeptide encoded by said nucleic acid is an immunostimulant.

41. (previously presented) The isolated nucleic acid of Claim 39 having at least 90% nucleic acid sequence identity to:

- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);
- (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
- (d) the nucleic acid sequence of (SEQ ID NO: 289);
- (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
- (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

wherein the polypeptide encoded by said nucleic acid is an immunostimulant.

42. (previously presented) The isolated nucleic acid of Claim 39 having at least 95% nucleic acid sequence identity to:

- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);
- (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
- (d) the nucleic acid sequence of (SEQ ID NO: 289);
- (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
- (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

wherein the polypeptide encoded by said nucleic acid is an immunostimulant.

43. (previously presented) The isolated nucleic acid of Claim 39 having at least 99% nucleic acid sequence identity to:

- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);

- (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
- (d) the nucleic acid sequence of (SEQ ID NO: 289);
- (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
- (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

wherein the polypeptide encoded by said nucleic acid is an immunostimulant.

44. (previously presented) An isolated nucleic acid comprising:

- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);
- (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
- (d) the nucleic acid sequence of (SEQ ID NO: 289);
- (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
- (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927.

45. (previously presented) The isolated nucleic acid of Claim 44 comprising a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290).

46. (previously presented) The isolated nucleic acid of Claim 44 comprising a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290), lacking its associated signal peptide.

47. (previously presented) The isolated nucleic acid of Claim 44 comprising a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290).

48. (canceled).

49. (previously presented) The isolated nucleic acid of Claim 44 comprising the nucleic acid sequence of (SEQ ID NO: 289).

50. (previously presented) The isolated nucleic acid of Claim 44 comprising the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289).

51. (previously presented) The isolated nucleic acid of Claim 44 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 209927.

52. (currently amended) An isolated nucleic acid molecule consisting of a fragment of the nucleic acid sequence of SEQ ID NO: 289, or a complement thereof, that specifically hybridizes to, under stringent conditions to:

- (a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO: 290);
- (b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO 290), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO: 290);
- (d) the nucleic acid sequence of (SEQ ID NO: 289);
- (e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO: 289); or
- (f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

~~wherein said polypeptide induces proliferation of stimulated T lymphocytes in a mixed lymphocyte reaction, and~~

wherein said stringent conditions are hybridization in 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1%

SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

53-54. (canceled)

55. (previously presented) A vector comprising the nucleic acid of Claim 39.

56. (previously presented) The vector of Claim 55, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

57. (previously presented) A host cell comprising the vector of Claim 55.

58. (previously presented) The host cell of Claim 57, wherein said cell is a CHO cell, an *E. coli* or a yeast cell.